Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $13.75

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a consensus recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $13.75.

A number of research firms have recently weighed in on TBPH. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Finally, TD Cowen lowered their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $8.21 on Wednesday. The firm has a market capitalization of $401.63 million, a P/E ratio of -9.55 and a beta of 0.24. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71. The company’s fifty day moving average price is $8.44 and its 200-day moving average price is $8.83.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter in the previous year, the company earned ($0.28) EPS. Equities analysts anticipate that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Theravance Biopharma news, major shareholder Eli Samaha bought 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the transaction, the insider now directly owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at $3,023,685. The disclosure for this sale can be found here. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. grew its position in Theravance Biopharma by 41.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock worth $5,005,000 after acquiring an additional 163,951 shares during the period. Marshall Wace LLP grew its position in Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares during the period. Squarepoint Ops LLC purchased a new position in Theravance Biopharma in the second quarter worth approximately $986,000. Wellington Management Group LLP grew its position in Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after acquiring an additional 116,164 shares during the period. Finally, Bank of Montreal Can grew its position in Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 93,702 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.